West Coast Research LLC              
                                     San Ramon, CA  •  Fremont, CA                                    
Current Studies
 
West Coast Research of San Ramon and Fremont are currently looking for study participants for the following studies: 
  1. Weight Loss
  2. Type 2 Diabetes (1)
  3. Type 2 Diabetes (2)
  4. Gout (1)
  5. Gout (2)
  6. Lupus (Fremont Location)
Future studies include: GERD, High Cholesterol, Coronary Heart Disease, Type 2 Diabetes, Sun Damage, Back Pain,  Erectile Dysfunction, Hypertension, COPD, IBS, Opioid Constipation

Study participants will receive the study drug, and all study related testing and examinations at no cost. Compensation for time and travel may be available.

1) Weight Loss

The drug involved in this study is Lorcaserin HCL.  Lorcaserin HCL has been approved by the United States Food and Drug Administration. (FDA) as an addition to a reduced-calorie diet and exercise, for chronic weight management.  The long-term effects on cardiovascular disease and prevention of type 2 diabetes have not been studied: this research will study the effect of long term use of Lorcaserin HCL.

Study participants will receive the study drug, and all study related testing and examinations at no cost. Compensation for time and travel may be available.

If you are interested in more information, please contact our office at 925-413-1451 or studies@westcoastresearch.com.

2) Type 2 Diabetes Study (1)

If you have been diagnosed with type 2 diabetes, you may be eligible to participate in a clinical research study.

This is a research study to test an investigational drug (MK-3102) that has not been approved by the United States Food and Drug Administration (FDA) for sale. MK-3102 is being developed as a once-weekly treatment for type 2 diabetes mellitus (T2DM).

This study will test MK-3102 in patients with T2DM whose A1C (a long term measure of blood glucose control and indicates how well your diabetes is controlled) is ≥7.0% and ≤10.0%; patients who were on diet or exercise alone; on stable dose of metformin, or other diabetic drugs continuously for the last 12 weeks, or stable dose of insulin (e.g., if the usual dose is 50 U/day, doses of 45-55 U/day would be considered as stable) during
the last 12 weeks; and those who have a pre-existing heart related disease such as heart attack, surgery of the heart, stroke etc. During this study, MK-3102 will be compared with placebo (look-alike with no active ingredients).


 Y
ou may qualify for our research research study if you:
  • 40 years of age or older
  • have type 2 diabetes
  • have a pre-existing heart related disease such as heart attack, surgery of the heart, stroke etc.

Study participants will receive the study drug, and all study related testing and examinations at no cost. Compensation for time and travel may be available.

If you are interested in more information, please contact our office at 925-413-1451 or 
studies@westcoastresearch.com.

2) Type 2 Diabetes Study (2)

If you have been diagnosed with type 2 diabetes,
you may be eligible to participate in a clinical research study.

Dapagliflozin is a drug that was developed for the treatment of type 2 diabetes by the sponsoring companies (AstraZeneca and Bristol-Myers Squibb). Dapagliflozin lowers glucose (sugar) levels in the blood by lowering the effect of specific molecules (small particles) in your body called sodium-glucose transporters. Under normal circumstances, the sodium-glucose transporters in the kidney prevent glucose in your blood stream from leaving your body through your urine. Dapagliflozin inhibits the sodium-glucose transporters and lowers your blood glucose by allowing glucose removal through the urine. Dapagliflozin may also mildly decrease body weight and lower blood pressure in certain people. For these reasons, dapagliflozin may have positive effects on risk factors for cardiovascular events.

This study is being carried out to see if a drug called dapagliflozin when added to your
current treatment for diabetes is effective in reducing cardiovascular events such as heart attack, stroke, and death from heart disease, when compared with placebo (inactive pill having no effect).


You may qualify for our research research study if you:
  • 40 years of age or older
  • have type 2 diabetes
Study participants will receive the study drug, and all study related testing and examinations at no cost. Compensation for time and travel may be available.

If you are interested in more information, please contact our office at 925-413-1451 or 
studies@westcoastresearch.com.

3) Gout Study (1)

This is a 5-9 year study to evaluate the safety of Febuxostat (Uloric) and Allopurinol. Study-related medical care and services are provided at no cost to study participants. Compensation for time and travel will be provided.

You may qualify to participate if you:

  • Female 55 years or older
  • Male 50 years or older
  • Have gout
Study participants will receive the study drug, and all study related testing and examinations at no cost. Compensation for time and travel may be available.

If you are interested in more information, please contact our office at 925-413-1451 or studies@westcoastresearch.com.

4) Gout  Study (2)

The purpose of this 3 month study is to evaluate the effectiveness and safety of an investigational new febuxostat (Uloric)  tablet (XR) in comparison with the marketed product (febuxostat IR (Uloric)) and placebo (inactive substance) in subjects with gout.

You may qualify for an gout research study if you:

  • 18 years of age older
  • Diagnosed with gout

There are other study requirements that will determine whether individuals may participate in this clinical research study.

Qualified study participants will receive gout medication or placebo and study related care for gout. Reimbursement for time and travel may be provided. 

If you are interested in more information, please contact our office at 925-413-1451 or studies@westcoastresearch.com.


6) Lupus (Fremont Location)

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab.

If you are interested in more information, please contact our office at 925-413-1451 or studies@westcoastresearch.c
om.

Contact Information 

To find out more information about a specific study, please call 925-413-1451 or email
 studies@westcoastresearch.com.  Our staff will be able to tell you more about the research study and answer your questions.


Click here to be added to our database and notified of future studies

  Study Documents


Please download and complete the indicated forms after calling for an appointment.

Registration Form
Medical History Form
Request for Medical Records Form
General Office Information and Directions - San Ramon
General Office Information and Directions - Fremont